IMR Press / CEOG / Volume 43 / Issue 3 / DOI: 10.12891/ceog2143.2016

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Diagnosis of antenatal Bartter syndrome
Show Less
1 Department of Maternal Fetal Medicine, The Royal Prince Alfred Hospital, Camperdown, NSW
2 The Prince of Wales Hospital, Sydney, NSW (Australia)
Clin. Exp. Obstet. Gynecol. 2016, 43(3), 453–454; https://doi.org/10.12891/ceog2143.2016
Published: 10 June 2016
Abstract

Established facts: Bartter syndrome is a rare heterogeneous group of autosomal-recessive salt-losing renal tubular disorders that can present in fetal life (antenatal Bartter syndrome; ABS) as “unexplained” early-onset polyhydramnios, often associated with growth restriction. Prenatal diagnosis of the condition involves assessment of amniotic fluid biochemistry in a setting of polyuric polyhydramnios; with elevated chloride levels considered a consistent and diagnostic finding. Other amniotic fluid biochemical markers have been described, notably increased aldosterone levels, and low total protein levels. Novel insight: Antenatal Bartter syndrome is a heterogeneous group of renal disorders. While certain biochemical features in amniotic fluid might heighten suspicion, final diagnosis can only be made in the postnatal setting. In the setting of unexplained severe polyhydramnios, clinicians should continue to entertain the diagnosis of antenatal Bartter Syndrome and maintain neonatal surveillance, even if amniotic fluid markers do not support the diagnosis.
Keywords
Antenatal Bartter syndrome
Share
Back to top